Envisia Therapeutics Releases Interim ENV515 (Travoprost XR) Phase II Data Demonstrating 11-Month Duration-Of-Action After A Single Dose In Patients With Glaucoma

By February 2, 2017 BioPharma No Comments

  Life Sciences Jobs   …
Source: BioSpace